Dandelion Health, a leader in real-world data (RWD) and clinical AI, has announced groundbreaking results from a study showing that GLP-1 medications could be effective in primary prevention for cardiovascular disease (CVD) in 44 million additional at-risk patients. This research, conducted using the newly launched Clinical AI Marketplace, highlights the transformative potential of AI in advancing precision medicine and personalized care.
Key Features of the Clinical AI Marketplace
- Innovative Research Platform: The Clinical AI Marketplace allows life sciences organizations to conduct novel research more efficiently and cost-effectively than traditional clinical trials. It utilizes validated AI algorithms and robust, representative RWD to generate actionable insights.
- Comprehensive Data Utilization: The platform excels in interpreting unstructured RWD, such as medical images and provider notes, which often contain valuable insights about treatment responses and patient outcomes.
- AI Algorithm Validation: Dandelion’s Marketplace validates AI algorithms for performance and equity, ensuring high-quality and unbiased results.
Study Insights
- Objective: The study aimed to explore if GLP-1 medications could serve as a primary prevention tool for reducing cardiovascular events among patients who have not yet experienced severe CVD.
- Methodology: Utilizing its GLP-1 data library, Dandelion conducted the study in just six weeks, at a fraction of the cost and time of traditional clinical trials. The study incorporated a broader population, including “clinically silent” patients who were not included in earlier trials like Novo Nordisk’s SELECT trial.
- Findings: The study used AI to predict MACE risk reduction from GLP-1s, revealing a potential 15%–20% decrease in risk after three years. This suggests that if GLP-1s were administered to the additional 44 million patients, it could prevent approximately 34,000 myocardial infarctions and strokes annually.
Leadership Perspectives
- Shivaani Prakash, MSc, PhD, Head of Data at Dandelion Health
- “The integration of diverse, multimodal data with validated AI reshapes clinical research, enabling studies on a much larger scale and at reduced costs and times.”
- Elliott Green, Co-founder and CEO of Dandelion Health
- Emphasized the impact of accelerated drug development and commercialization in providing timely treatments and improving patient outcomes on a global scale.
Dandelion Health’s study and the launch of the Clinical AI Marketplace represent a significant leap forward in utilizing AI and RWD for clinical research. This innovative approach not only enhances the efficiency of studies but also opens up new possibilities for preventing cardiovascular diseases and improving patient care.
